CN101700271B - Traditional Chinese medicine preparation for treating apoplexy sequelae - Google Patents
Traditional Chinese medicine preparation for treating apoplexy sequelae Download PDFInfo
- Publication number
- CN101700271B CN101700271B CN2009102190601A CN200910219060A CN101700271B CN 101700271 B CN101700271 B CN 101700271B CN 2009102190601 A CN2009102190601 A CN 2009102190601A CN 200910219060 A CN200910219060 A CN 200910219060A CN 101700271 B CN101700271 B CN 101700271B
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- blood
- radix
- medicine preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a traditional Chinese medicine preparation for treating apoplexy sequelae, which is a medicament prepared from such raw materials as astragalus mongholicus, ground beetle, radix notoginseng and radix puerariae. The invention has the efficacy of supplementing qi, activating blood circulation, dissolving stasis and smoothing collaterals, treats apoplexy sequelae, can effectively prevent apoplexy and has the advantages of quick effects, favorable curative effects and no toxic or side effects.
Description
Technical field
The invention belongs to medical technical field, be specifically related to a kind of Chinese medicine preparation for the treatment of apoplexy sequela.
Background technology
Acute cerebrovascular disease is that cerebrovascular disease causes the cerebral lesion that focal disturbance of blood circulation causes, it is common and the disease of serious harm human health, it can be the unexpected thrombosis of cerebrovascular, cerebral embolism causes ischemic brain infarction, also can be that rupture of blood vessel in brain produces cerebral hemorrhage, it is hurried to fall ill, and recovers slower, and leaves over dysfunction in various degree.Often with neurological symptom, hemiplegia, numb limbs and tense tendons, pain contracture, have a dizzy spell, dull expression, facial hemiparalysis, slurred speech, slobbering, severe patient stupor and dead claims cerebrovascular accident, apoplexy or apoplexy clinically again.The mortality rate height, the disability rate height.It is reported that 80% patients with cerebrovascular disease has limbs disturbance in various degree, wherein 43.7% patient can't take care of oneself.Be that the whole world causes one of three dead big diseases, annual morbidity is about 0.1～0.2%, and annual death rate is about 0.06～1.02%, and each age group all has morbidity.China is apoplexy country occurred frequently, and according to statistics, there are 2,000,000 to 2,500,000 New Development patients with cerebrovascular disease in the whole nation every year, and wherein 11% is young and middle-aged people, an example of age minimum only 23 years old, and continue the trend of rejuvenation in addition.The social economy's burden that is used for apoplexy every year is up to hundred million yuan of hundreds ofs.
Acute cerebrovascular disease main hazard factor has hypertension, heart disease, diabetes, transient ischemic attack history, smoking, drinks, hyperlipemia, atherosclerosis etc.Clinical common be divided into hemorrhagic (cerebral hemorrhage, subarachnoid hemorrhage) and ischemic (cerebral artery thrombosis formation, cerebral embolism) two big classes.The pathologic basis of most acute cerebrovascular diseasees is atherosclerosis and arteriolosclerosis, cerebral hemorrhage that pathological process is hemorrhage for blood vessel wall is broken or subarachnoid hemorrhage and because of vascular occlusion causes the cerebral infarction that blood supply district ischemia forms can separately or mix existence clinically.
The treatment of cerebrovascular accident acute stage, most critical are to impel consciously, eliminate cerebral edema, the protection brain cell.These all can be by the having one's ideas straightened out of the traditional Chinese medical science, clearing away phlegm, relieve dizziness, high fever, infantile convulsions, epilepsy, etc., rush down inferior method of treatment realizes.What face at present is the form improvement of treatment side's medicine, should develop the definite Chinese medicine preparation of more clinical efficacies, and this is the direction that we make great efforts.
Summary of the invention
The objective of the invention is to overcome the deficiencies in the prior art, provide a kind of determined curative effect, side effect little, the Chinese medicine preparation of the treatment apoplexy sequela of taking convenience.
For solving the problems of the technologies described above, the technical solution used in the present invention is: a kind of Chinese medicine preparation for the treatment of apoplexy sequela is characterized in that being made by the raw material of following weight portion:
2.5～4.5 parts of the Radixs Astragali, 1.5～3.5 parts of Eupolyphaga Seu Steleophagas, 0.5～2.5 part of Radix Notoginseng, 1.5～3.5 parts of Radix Puerariaes.
The preferred technical solution of the present invention is: a kind of Chinese medicine preparation for the treatment of apoplexy sequela is characterized in that being made by the raw material of following weight portion:
3～4 parts of the Radixs Astragali, 2～3 parts of Eupolyphaga Seu Steleophagas, 1～2 part of Radix Notoginseng, 2～3 parts of Radix Puerariaes.
Best-of-breed technology scheme of the present invention is: a kind of Chinese medicine preparation for the treatment of apoplexy sequela is characterized in that being made by the raw material of following weight portion:
3.5 parts of the Radixs Astragali, 2.5 parts of Eupolyphaga Seu Steleophagas, 1.5 parts of Radix Notoginseng, 2.5 parts of Radix Puerariaes.
Drug action mechanism of the present invention is as follows:
The Radix Astragali: nature and flavor are sweet, warm.Return lung, spleen channel.Have benefit and defend consolidating superficial resistance, inducing diuresis to remove edema, poison holding, the effect of granulation promoting.That can treat that internal injury overstrain, diarrhea due to hypofunction of the spleen, proctoptosis, deficiency of vital energy blood prostration, metrorrhagia and leukorrhagia, spontaneous perspiration, night sweat, arthralgia due to stagnation of blood, edema, carbuncle do not burst or burst does not hold back and the disease of all weakness of QI blood deficiency etc.
Eupolyphaga Seu Steleophaga: nature and flavor are salty, and are cold.Return Liver Channel.Has removing blood stasis with potent drugs blood, the effect of reuniting the fractured tendons and bones.Be used for the muscles and bones folding and hinder blood stasis amenorrhea ， mass in the abdomen mass in the abdomen.
Radix Notoginseng: sweet, the little hardship of nature and flavor, temperature.Return liver, stomach warp.Has the dissipating blood stasis hemostasis, the effect of subduing swelling and relieving pain.Be used for spitting of blood, spit blood, epistaxis is had blood in stool, metrorrhagia, traumatic hemorrhage, breast ventral spine pain, tumbling and swelling.
Radix Puerariae: nature and flavor are sweet, hot, cool.Return spleen, stomach warp.Have expelling pathogenic factors from muscles for reducing heat, promote the production of body fluid, rash, the effect of yang invigorating antidiarrheal.Be used for fever caused by exogenous pathogens headache, stiff nape and back, thirsty, quench one's thirst, measles without adequate eruption, hematodiarrhoea is had loose bowels; The hypertension neck pain.
Effect of the present invention: benefiting QI for activating blood circulation, disperse blood stasis and dredge collateral.
Cure mainly: the blood stagnancy due to deficiency of QI of apoplexy, venation block card.Be used for blood stasis due to qi deficiency, the apoplexy sequela due to the venation block, disease is seen hemiplegia, numb limbs and tense tendons, pain contracture, is had a dizzy spell, dull expression, facial hemiparalysis, slurred speech, slobbering.
Side of the present invention separates: wind was by due to blood stasis due to qi deficiency, the venation block among we controlled.The deficiency of vital energy is this, and blood stasis is for mark, because of the deficiency of vital energy causes blood stasis, because of blood stasis makes venation block.The brain ischemia, muscle, muscle arteries and veins lose foster and see hemiplegia, facial hemiparalysis, stiff tongue and retardation in speech, all diseases of numb limbs and tense tendons.Control method with benefiting QI for activating blood circulation, disperse blood stasis and dredge collateral.
The Radix Astragali is monarch in the side, sweet Wen Chunyang, and big spleen reinforcing lung vigour makes gas prosperous capable with short blood.Eupolyphaga Seu Steleophaga is a minister, salty-coldly goes into blood system, and merit is arrogated to oneself removing blood stasis with potent drugs blood, is the key medicine of blood circulation promoting and blood stasis dispelling.Two medicines match, and inrigorating qi and promoting blood circulation has blood stasis dispelling and do not hinder just wonderful.The sweet temperature of Radix Notoginseng, kind blood stasis dispelling blood, the analgesic therapy of invigorating blood circulation, and blood stasis dispelling blood and do not hinder fresh blood are the treating blood disorders quality goods, help Eupolyphaga Seu Steleophaga to invigorate blood circulation, and are adjuvant drug.The clear sun of Radix Puerariae elevate a turnable ladder taste draws all medicines and reaches in the part of the body cavity above the diaphragm housing the heart and lungs, with being messenger drug.All medicines match, inrigorating qi and promoting blood circulation, and disperse blood stasis and dredge collateral, giving consideration to both the incidental and fundamental is invigorated blood circulation and is not just hindered, and makes vigour good, the blood vessels smoothness, all diseases can be healed.Though the apoplectic hemiplegia disease of apoplex involving the channels and collaterals, still in wind sequela among the internal organs, and see the hemiplegia person that belongs to the syndrome of blood stasis due to qi deficiency, that uses all has a significant curative effect.
The present invention compared with prior art has the following advantages:
1. the Chinese herbal medicine each component selected for use of the present invention meets " The Drug Administration Law of People's Republic of China " and " regulation that Chinese pharmacopoeia version in 2005 is an one, utilize comprehensive function prevention and treatment cerebral thrombosis, cerebral ischemia and the sequela of the Chinese medicine of respectively distinguishing the flavor of, no any additives, nontoxic to human body.Show that through animal acute toxicity experiment the animal of being tested does not see any toxic reaction, safety of medicine is reliable.
2. the present invention need not decoct, no bitterness sense, rich in proteins, glucose, glucuronic acid, volatile oil, pectin, fructose, organic acid, lecithin, vitamin, aminoacid in the medicine, the main various trace elements such as saponin, polysaccharide, flavone, plant sterol and calcium that contain, be beneficial to absorption of human body, health invigorating, and taking convenience.
3. the present invention can treat apoplexy sequela effectively, and prevention of stroke also has better curative effect, has improved patient's life quality and the time greatly, and higher healing rehabilitation efficacy is arranged.
Below by embodiment the present invention is described in further detail.
The specific embodiment
Embodiment 1
The medicine composition is counted by weight: 3.5 parts of the Radixs Astragali, 2.5 parts of Eupolyphaga Seu Steleophagas, 1.5 parts of Radix Notoginseng, 2.5 parts of Radix Puerariaes.
Preparation method is: above four flavors, and Radix Notoginseng powder is broken into fine powder, and Eupolyphaga Seu Steleophaga and powder of Radix Puerariae are broken into coarse powder, after the Radix Astragali is soaked 2 hours, decoct twice, and each 2 hours, decocting liquid filtered while hot, and filtrate decompression is concentrated into the thick paste that relative density is 1.30 (50 ℃); Medicinal residues add above-mentioned coarse powder, reflux twice with 4 hours post-heating of 75% soak with ethanol, and each 2 hours, extracting solution filtered, and merging filtrate reclaims ethanol, is evaporated to the thick paste of 1.30 (50 ℃); Two thick pastes and above-mentioned fine powder mixing are granulated, and at 60 ℃ of following drying under reduced pressure, pulverize 65 mesh sieves, incapsulate, and every dress 0.45g makes 1000, promptly.
Embodiment 2
The medicine composition is counted by weight: 2.5 parts of the Radixs Astragali, 1.5 parts of Eupolyphaga Seu Steleophagas, 2.5 parts of Radix Notoginseng, 3.5 parts of Radix Puerariaes.
Preparation method is with embodiment 1.
Embodiment 3
The medicine composition is counted by weight: 4.5 parts of the Radixs Astragali, 3.5 parts of Eupolyphaga Seu Steleophagas, 0.5 part of Radix Notoginseng, 1.5 parts of Radix Puerariaes.
Preparation method is with embodiment 1.
Embodiment 4
The medicine composition is counted by weight: 2.8 parts of the Radixs Astragali, 1.7 parts of Eupolyphaga Seu Steleophagas, 2.2 parts of Radix Notoginseng, 3.3 parts of Radix Puerariaes.
Preparation method is with embodiment 1.
Embodiment 5
The medicine composition is counted by weight: 3 parts of the Radixs Astragali, 2 parts of Eupolyphaga Seu Steleophagas, 2 parts of Radix Notoginseng, 3 parts of Radix Puerariaes.
Preparation method is with embodiment 1.
Embodiment 6
The medicine composition is counted by weight: 4 parts of the Radixs Astragali, 3 parts of Eupolyphaga Seu Steleophagas, 1 part of Radix Notoginseng, 2 parts of Radix Puerariaes.
Preparation method is with embodiment 1.
Embodiment 7
The medicine composition is counted by weight: 3.2 parts of the Radixs Astragali, 2.3 parts of Eupolyphaga Seu Steleophagas, 1.8 parts of Radix Notoginseng, 2.7 parts of Radix Puerariaes.
Preparation method is with embodiment 1.
Embodiment 8
The medicine composition is counted by weight: 3.8 parts of the Radixs Astragali, 2.7 parts of Eupolyphaga Seu Steleophagas, 1.2 parts of Radix Notoginseng, 2.3 parts of Radix Puerariaes.
Preparation method is with embodiment 1.
Usage and dosage: oral, one time 4,3 times on the one.Half an hour ante cibum warm boiled water, one month is a course of treatment, obeys two courses of treatment altogether.
Criterion of therapeutical effect:
1. cure: symptom and sign disappear, and can live on one's own life substantially.
2. take a turn for the better: symptom and sign take a turn for the better, the action of energy cane, or basic life can be taken care of oneself.
3. do not heal: symptom and sign no change.
Further specify the therapeutic effect of medicine of the present invention below by the clinical practice example to the treatment apoplexy sequela.
For showing the therapeutic effect of medicine of the present invention, as follows through clinical test results to apoplexy sequela:
Treatment group clinical observation apoplexy sequela patient 348 examples, the age is 46～72 years old, male's 175 examples, women's 173 examples.The treatment group is taken the present invention's " yellow seven capsules ", and each 4, every day three times, eliminating cold for resuscitation water send down, and take half an hour ante cibum.One month is a course of treatment, take continuously two the course of treatment observe the curative effect.Cure 178 examples and account for 51.1%, 157 examples that take a turn for the better account for 45.1%, and more 13 examples do not account for 3.8%, and total effective rate reaches more than 96.2%.After two course of therapy, symptoms such as patient's hemiplegia, facial hemiparalysis, slurred speech all have obvious change or recovery from illness, and patient do not have any untoward reaction, and three big routine tests and hepatic and renal function detect no abnormal.
Matched group clinical observation apoplexy sequela patient 256 examples, the age is 48～59 years old, male's 152 examples, women's 104 examples, matched group are taken beneficial brain rehabilitation capsule, each 4, every day three times, eliminating cold for resuscitation water send down, and take half an hour ante cibum, one month is a course of treatment, take continuously two the course of treatment observe the curative effect, cure 101 examples and account for 39.5%, 23 examples that take a turn for the better account for 9.0%, more 132 examples do not account for 51.5%, and total effective rate reaches 48.5%.
Learning result by statistics proves: treatment group and matched group curative effect significant difference (P＜0.01), the curative effect of treatment group treatment apoplexy sequela obviously is better than matched group.
The present invention has carried out acute toxicity test: get 3 of mices during prerun, irritate the yellow seven capsule 's content 97.5g crude drug/kg of stomach (being equivalent to clinical 250 times with dosage), irritating the stomach volume is 0.5ml/10g, the no phenomena of mortality.Get 20 of mices subsequently and irritate stomach, observe and also do not have the phenomena of mortality or the appearance of other acute toxic reactions in 7 days by above-mentioned dosage.After observing end, put to death animal and perform an autopsy on sb, main organs no abnormality seen situation shows that yellow seven capsule toxicity are extremely low as a result.
The present invention has also carried out chronic toxicity test: get 63 of rats, be divided into three groups at random, be i.e. blank group (20), the large and small dosage group of yellow seven capsules (22 and 21).Male and female sub-cage rearing, each treated animal adaptability carry out administration after feeding and observing a week.The blank group is irritated the stomach ordinary water, and the large and small dosage group of yellow seven capsules is irritated the yellow seven capsule 's content 39g crude drug/kg of stomach (be about clinical human dosage 100 times), 19.5g crude drug/kg (be about clinical human dosage 50 times) respectively.Each treated animal filling body of stomach amasss and is the 1ml/100g body weight, once a day, and successive administration six months.The result shows: the body weight of each administration treated animal, activity, hair, feces, hematological examination, hepatic and renal function and blank group be there was no significant difference relatively; Important organs such as the administration treated animal heart, liver, kidney, lung, gross necropsy is not seen abnormal phenomenas such as hyperemia, edema, dirty body ratio, pathology sheet and blank group be there was no significant difference relatively.Show yellow seven capsules to the above-mentioned dosage of rat, the continuous irrigation stomach six months was safe.
In sum, the present invention is based on blood stasis due to qi deficiency, the apoplexy sequela due to the venation block is in conjunction with the etiology and pathogenesis and the Therapeutic Principle of the traditional Chinese medical science, prove by long-term clinical practice, its prescription is better than other prescription, through rationalizing Huang seven capsules of development, has benefiting QI for activating blood circulation, the effect of disperse blood stasis and dredge collateral, be applicable to blood stasis due to qi deficiency, the apoplexy sequela due to the venation block, disease is seen hemiplegia, numb limbs and tense tendons, pain contracture, is had a dizzy spell, dull expression, facial hemiparalysis, slurred speech, slobbering.Have that determined curative effect, dissolving are fast, release advantage rapidly, reach the purpose of quick relief of symptoms and treatment, be worth in clinical, applying.
Claims (3)
1. Chinese medicine preparation for the treatment of apoplexy sequela is characterized in that being made by the raw material of following weight portion:
2.5～4.5 parts of the Radixs Astragali, 1.5～3.5 parts of Eupolyphaga Seu Steleophagas, 0.5～2.5 part of Radix Notoginseng, 1.5～3.5 parts of Radix Puerariaes.
2. a kind of Chinese medicine preparation for the treatment of apoplexy sequela according to claim 1 is characterized in that being made by the raw material of following weight portion:
3～4 parts of the Radixs Astragali, 2～3 parts of Eupolyphaga Seu Steleophagas, 1～2 part of Radix Notoginseng, 2～3 parts of Radix Puerariaes.
3. a kind of Chinese medicine preparation for the treatment of apoplexy sequela according to claim 1 and 2 is characterized in that being made by the raw material of following weight portion:
3.5 parts of the Radixs Astragali, 2.5 parts of Eupolyphaga Seu Steleophagas, 1.5 parts of Radix Notoginseng, 2.5 parts of Radix Puerariaes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009102190601A CN101700271B (en) | 2009-11-19 | 2009-11-19 | Traditional Chinese medicine preparation for treating apoplexy sequelae |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009102190601A CN101700271B (en) | 2009-11-19 | 2009-11-19 | Traditional Chinese medicine preparation for treating apoplexy sequelae |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101700271A CN101700271A (en) | 2010-05-05 |
| CN101700271B true CN101700271B (en) | 2011-05-11 |
Family
ID=42155214
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009102190601A Expired - Fee Related CN101700271B (en) | 2009-11-19 | 2009-11-19 | Traditional Chinese medicine preparation for treating apoplexy sequelae |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101700271B (en) |
-
2009
- 2009-11-19 CN CN2009102190601A patent/CN101700271B/en not_active Expired - Fee Related
Non-Patent Citations (1)
| Title |
|---|
| 周志娴.《中医药治疗中风后遗症研究近况》.《云南中医学院学报》.2006,第29卷(第8期),149-152. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101700271A (en) | 2010-05-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104984316A (en) | Medicine for treating female cold in uterus | |
| CN101703686B (en) | Chinese medicinal composition for treating diabetes | |
| CN102579610B (en) | Chinese medicinal composition for treating cerebral hemorrhage and preparation method thereof | |
| CN103251878B (en) | Anti-fatigue traditional Chinese medicine composition | |
| CN104623600A (en) | Traditional Chinese medicine for treating peripheral neuritis and preparation method thereof | |
| CN103920058A (en) | Traditional Chinese medicine preparation for treating headache and preparation method thereof | |
| CN107737319A (en) | Improve Chinese medicine preparation of sleep quality and preparation method thereof | |
| CN101700271B (en) | Traditional Chinese medicine preparation for treating apoplexy sequelae | |
| CN103202985A (en) | Traditional Chinese medicine used for treating lumbar spondylosis, cervical spondylosis, sciatica and rheumatism and preparation method thereof | |
| CN102935185A (en) | Pills for treating neurasthenia and preparation method | |
| CN100496542C (en) | Chinese traditional medicine composition for treating arthralgia syndrome of cervical spondylopathy and its preparation | |
| CN105213758A (en) | A kind of Chinese medicine composition for the treatment of chronic pneumonia and preparation method thereof | |
| CN105169078A (en) | Traditional Chinese medicinal composition for treating diabetes | |
| CN104971241A (en) | Traditional Chinese medicinal composition for treating cerebral thrombus, and preparation method thereof | |
| CN110339323A (en) | A kind of Chinese medicine composition and its preparation method and application for treating bradycardia | |
| CN109700887A (en) | A kind of Chinese medicine composition and preparation method thereof for treating impotence and premature ejaculation | |
| CN103349709B (en) | Traditional Chinese medicine preparation capable of tonifying qi and yin and nourishing liver and kidney | |
| CN110464803A (en) | A kind of Chinese medicine composition and preparation method thereof for reducing blood pressure | |
| CN101607007B (en) | Traditional Chinese medicine preparation for treating cerebral circulation insufficiency | |
| CN105832934A (en) | Traditional Chinese medicine for treating hypertension | |
| CN105327064A (en) | Traditional Chinese medicinal preparation for treating climacteric arthritis | |
| CN105363016A (en) | Medicine for treating headache | |
| CN103961677A (en) | Traditional Chinese medicine mixture for treating arrhythmia | |
| CN104984298A (en) | Traditional Chinese medicine preparation having weight-losing toxin-expelling efficacies | |
| CN103479821B (en) | Chinese medicine composition of a kind of the kidney invigorating benefit blood and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CB03 | Change of inventor or designer information |
Inventor after: Yin Mingteng Inventor before: Yin Zijun |
|
| COR | Change of bibliographic data | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110511 Termination date: 20171119 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |